

2005 Current Fiscal Year Report: State Pharmaceutical Assistance Transition Commission

Report Run Date: 04/26/2024 01:46:02 PM

1. Department or Agency

Department of Health and Human
Services

2. Fiscal Year

2005

3. Committee or Subcommittee

State Pharmaceutical Assistance
Transition Commission

3b. GSA

Committee No.

21479

4. Is this New During Fiscal Year?

5. Current Charter	6. Expected Renewal Date	7. Expected Term Date
--------------------	--------------------------	-----------------------

No	03/19/2004	01/31/2005
----	------------	------------

8a. Was Terminated During Fiscal Year?

Yes

8b. Specific Termination Authority

Section 106 of MMA
P.L. 108-173

8c. Actual Term Date

01/19/2005

9. Agency Recommendation for Next Fiscal Year

Terminate

10a. Legislation Req to Terminate?

No

10b. Legislation Pending?

Enacted

11. Establishment Authority

Statutory (Congress Created)

12. Specific Establishment Authority

Section 106 of MMA P.L.
108-173

13. Effective Date

12/08/2003

14. Committee Type

Continuing

14c. Presidential?

No

15. Description of Committee

Other Committee

16a. Total Number of Reports

No Reports for
this Fiscal Year

17a. Open

1 17b. Closed 0 17c. Partially Closed 0 Other Activities 0 17d. Total 1

Meetings and Dates

Purpose

Start

End

Agenda: The commission will spend the majority of the meeting presenting their findings as a result of research and deliberations regarding the transitional issues facing SPAPs.

10/14/2004 - 10/14/2004

Number of Committee Meetings Listed: 1

	Current FY	Next FY
18a(1). Personnel		
Pmts to Non-Federal Members	\$0.00	\$0.00
18a(2). Personnel		
Pmts to Federal Members	\$0.00	\$0.00
18a(3). Personnel		
Pmts to Federal Staff	\$0.00	\$0.00
18a(4). Personnel		
Pmts to Non-Member Consultants	\$0.00	\$0.00
18b(1). Travel and Per Diem to Non-Federal Members	\$256,960.00	\$256,960.00
18b(2). Travel and Per Diem to Federal Members	\$0.00	\$0.00
18b(3). Travel and Per Diem to Federal Staff	\$0.00	\$0.00
18b(4). Travel and Per Diem to Non-member Consultants	\$0.00	\$0.00
18c. Other(rents,user charges, graphics, printing, mail, etc.)	\$0.00	\$0.00
18d. Total	\$256,960.00	\$256,960.00
19. Federal Staff Support Years (FTE)	0.40	0.40

20a. How does the Committee accomplish its purpose?

The committee will accomplish its purpose by addressing the unique transitional issues facing

State pharmaceutical assistance programs and program participants due to the implementation of the voluntary prescription drug benefit program under Medicare part D.

20b. How does the Committee balance its membership?

The State Pharmaceutical Assistance Transition Commission consists of the Secretary, or his designee and up to 70 members including the Chair. The panel membership includes a broad spectrum of industry professionals, which include:1) A representative of each Governor of each State that the Secretary identifies as operating on a statewide basis a State pharmaceutical assistance program that provides for eligibility and benefits comparable or more generous than the low-income assistance and eligibility and benefits offered under section 1860D-14 of the Social Security Act:2) Representatives from other States identified by the Secretary with other SPAP's in operation 3) Representatives of organizations with an inherent interest in program participants or the program itself4) Representatives of Medicare Advantage organizations, pharmaceutical benefits managers and other private health insurance plans.

20c. How frequent and relevant are the Committee Meetings?

Meetings will be held once each calendar quarter, and will be called by the Chairperson.

20d. Why can't the advice or information this committee provides be obtained elsewhere?

Section 106 of Medicare Prescription Drug Improvement and Modernization Act of 2003 (MMA)(P.L. 108-173)requires the Secretary of HHS to establish a State Pharmacy Assistance

Transition Commission. The commission must submit to the President and the Congress a report that contains a detailed proposal (including specific legislative or administrative recommendations, if any) and other recommendations as the commission deems appropriate.

20e. Why is it necessary to close and/or partially closed committee meetings?

Meetings are not closed. All meetings shall be open to the public except as determined otherwise by the Secretary or other official to whom the authority has been delegated. Notices of meetings are given to the public in the Federal Register, and there will be records of the meeting proceedings kept, as required by applicable laws and departmental regulations. In the event that a portion of a meeting is closed to the public, a report will be prepared that contains at a minimum a list of members and their business addresses, the Panel's function, dates and places of meetings, and a summary of Panel activities and recommendations made during the fiscal year. A copy of the report will be provided to the Department Committee Management Officer.

21. Remarks

Designated Federal Officer

Marge Watchorn Health Insurance Specialist

Committee Members	Start	End	Occupation	Member Designation
Barnes, Clifford	03/01/2004	01/31/2005	Attorney, Epstein, Becker & Green P.C. 1227 25th St, NW Washington DC 20037	Representative Member

Boswell, Donna	03/01/2004	01/31/2005	Partner, Hogan & Hartson LLP Columbia Square 555 13th Street NW Washington DC 20004-1109 Director of Health Care Purchasing Minnesota	Representative Member
Chase, James	03/01/2004	01/31/2005	Department of Human Services 444 Lafayette Street St. Paul MN 55155 Vice President, Pharmacy Services The Regence Group	Representative Member
Clark, David	03/01/2004	01/31/2005	200 SW Market Suite 1200 Portland OR 97201 Associate Professor Division of Clinical and Administrative Pharmacy	Representative Member
Currie, Jay	03/01/2004	01/31/2005	College of Pharmacy The University of Iowa Deputy Director, Office of Ohio Health Plans Ohio Department of Job and Family Services Office of Ohio Health	Representative Member
Edwards, Barbara	03/01/2004	01/31/2005	Plans 30 East Broad Street 31st Floor Columbus OH 43214 Secretary, Pennsylvania Department of	Representative Member
Eisenhower, Nora	03/01/2004	01/31/2005	Aging 555 Walnut Street 5th Floor Harrisburg PA 17101-1919	Representative Member

Member Name	Start Date	End Date	Address	Role
Faiks, Janice	03/01/2004	01/31/2005	Assistant General Counsel Pharmaceutical Research and Manufacturers of America 1100 15th St, NW, Suite 900 Washington DC 20005	Representative Member
Garner, Dewey	03/01/2004	01/31/2005	Chair and Professor of Pharmacy Administration School of Pharmacy University of Mississippi PO Box 1848 University MS 38677	Representative Member
Greenrose, Karen	03/01/2004	01/31/2005	President American Association of Preferred Provider Organizations PO Box 429 Jeffersonville TN 47131-0429	Representative Member
Henneberry, Joan	03/01/2004	01/31/2005	Director Consulting Research Government Health Services Policy Studies, Inc 1899 Wynkoop St Suite 300 Denver CO 80202	Representative Member
Hines, Laurie	03/01/2004	01/31/2005	Executive Director Missouri Senior Rx Program 205 Jefferson St Room 1310 Jefferson City, MO 65102	Representative Member

Liveratti, Mary	03/01/2004	01/31/2005	Deputy Director, Nevada Department of Human Resources 505 E. King St. Room 600 Carson City NV 89701 Administrator for Medical Programs Illinois Department of Public Aid 201 South Grand Ave East Springfield IL 62763-0001	Representative Member
Murphy, Anne	03/01/2004	01/31/2005	Director, New York State EPIC Program One Corporate Plaza 260 Washington Avenue Extension Suite 101 Albany NY 12203	Representative Member
Naglieri, Julie	03/01/2004	01/31/2005	Vice President Walgreen Company, Deerfield, IL Senior Director/Senior Medical Economist	Representative Member
O'Dell, Dennis	03/01/2004	01/31/2005	HealthPartners, Inc. 8100 34th Ave South Minneapolis MN 55440-1309 Deputy Commissioner, NJ Department of Health and Senior Services P.O. Box 360 Trenton NJ 08625-0360	Representative Member
Power, Robert	03/01/2004	01/31/2005		Representative Member
Reinhard, Susan	03/01/2004	01/31/2005		Representative Member

			Bureau Chief, Florida Medicaid Pharmacy Services Florida Agency for Health Care Administration 2727 Mahan Drive Tallahassee FL 32308	Representative Member
Richard, Sybil	03/01/2004	01/31/2005		
			United Seniors Association, Sun City, AZ Secretary State Office of Policy Management 450 Capitol Avenue Hartford CT 06106	Representative Member
Rohn-Nelson, Elizabeth	03/01/2004	01/31/2005		
			Consultant, Schofield Consulting, Simsbury, CT ACS State Healthcare Prescription Benefits Management	Representative Member
Ryan, Marc	03/01/2004	01/31/2005		
			Northridge Center One Suite 400 365 Northridge Rd. Atlanta GA 30350	Representative Member
Schofield, Linda	03/01/2004	01/31/2005		
Schuh, Martin	03/01/2004	01/31/2005		

Number of Committee Members Listed: 23

Narrative Description

-commission terminated in January 2005

What are the most significant program outcomes associated with this committee?

Checked if
Applies

Improvements to health or safety	<input type="checkbox"/>
Trust in government	<input type="checkbox"/>
Major policy changes	<input type="checkbox"/>
Advance in scientific research	<input type="checkbox"/>

- | | |
|---|--------------------------|
| Effective grant making | <input type="checkbox"/> |
| Improved service delivery | <input type="checkbox"/> |
| Increased customer satisfaction | <input type="checkbox"/> |
| Implementation of laws or regulatory requirements | <input type="checkbox"/> |
| Other | <input type="checkbox"/> |

Outcome Comments

NA

What are the cost savings associated with this committee?

Checked if Applies

- | | |
|----------------------------|-------------------------------------|
| None | <input type="checkbox"/> |
| Unable to Determine | <input checked="" type="checkbox"/> |
| Under \$100,000 | <input type="checkbox"/> |
| \$100,000 - \$500,000 | <input type="checkbox"/> |
| \$500,001 - \$1,000,000 | <input type="checkbox"/> |
| \$1,000,001 - \$5,000,000 | <input type="checkbox"/> |
| \$5,000,001 - \$10,000,000 | <input type="checkbox"/> |
| Over \$10,000,000 | <input type="checkbox"/> |
| Cost Savings Other | <input type="checkbox"/> |

Cost Savings Comments

NA

What is the approximate Number of recommendations produced by this committee for the life of the committee?

0

Number of Recommendations Comments

NA

What is the approximate Percentage of these recommendations that have been or will be Fully implemented by the agency?

0%

% of Recommendations Fully Implemented Comments

NA

What is the approximate Percentage of these recommendations that have been or will be Partially implemented by the agency?

0%

% of Recommendations Partially Implemented Comments

NA

Does the agency provide the committee with feedback regarding actions taken to implement recommendations or advice offered?

Yes ☐ No ☐ Not Applicable ☒

Agency Feedback Comments

NA

What other actions has the agency taken as a result of the committee's advice or recommendation?

Checked if Applies

Reorganized Priorities	<input type="checkbox"/>
Reallocated resources	<input type="checkbox"/>
Issued new regulation	<input type="checkbox"/>
Proposed legislation	<input type="checkbox"/>
Approved grants or other payments	<input type="checkbox"/>
Other	<input type="checkbox"/>

Action Comments

NA

Is the Committee engaged in the review of applications for grants?

No

Grant Review Comments

NA

How is access provided to the information for the Committee's documentation?

Checked if Applies

Contact DFO	<input type="checkbox"/>
Online Agency Web Site	<input type="checkbox"/>

Online Committee Web Site



Online GSA FACA Web Site



Publications



Other



Access Comments

NA